D. Boral Capital stays Buy on Humacyte (HUMA) following MAA submission in Israel

D. Boral Capital analyst Jason Kolbert reiterated a Buy rating and $25.00 price target on Humacyte (NASDAQ: HUMA)

The analyst commented, "Humacyte announced the submission of a Marketing Authorization Application (MAA) in Israel for Symvess, its acellular tissue engineered vessel for arterial trauma repair, marking an important step in the company’s global commercialization strategy. The filing builds on prior FDA approval and clinical validation, while management also highlighted efforts to enable early access via hospital-by-hospital pathways ahead of formal approval. We view this as a strategic expansion into a high-need region with meaningful military and civilian trauma exposure, supporting the broader international adoption thesis."

For an analyst ratings summary and ratings history on Humacyte click here. For more ratings news on Humacyte click here.

Shares of Humacyte closed at $1.12 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Aurora Spine settles patent dispute, secures $600K insider loan
• Cantor Fitzgerald Reiterates Overweight Rating on Applied Materials (AMAT)